We examine Bristol Myers Squibb’s pipeline strategy and therapeutic priorities in 2026, as it faces a major patent cliff in the coming years.

Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of ...

Enanta Pharmaceuticals (NASDAQ:ENTA) used a presentation at the Citizens Life Sciences Conference to outline its evolving ...

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS ...

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

A dual-action HIV antibody–drug conjugate forces Env to open, then blocks it, boosting virus neutralization up to tenfold in ...

Completed Phase 1 pharmacokinetic (PK) clinical trial of denifanstat and resmetirom combinationPhase 2 trial of denifanstat/resmetirom ...

Hepatitis B virus (HBV) infection remains an urgent global health concern, affecting hundreds of millions of people and significantly heightening the risk of severe liver complications, including ...

Although the primary endpoint was not met, axitinib was associated with significantly increased PFS and ORR for patients with previously-treated, advanced extrapancreatic neuroendocrine tumors.

Drug conjugates (ADCs) developed at Institute of Science Tokyo combine a CD4 mimic with neutralizing antibodies for enhanced suppression of human immunodeficiency virus (HIV) infection. By targeting ...

NEW YORK – Diasorin announced on Thursday that it has been granted de novo authorization from the US Food and Drug Administration for a test to detect hepatitis delta virus on the Liaison XL automated ...